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ACR = American College of Rheumatology; ACR20 = ACR 20% response criteria; DMARD = disease-modifying antirheumatic drug; IL = inter-
leukin; MTX = methotrexate; RA = rheumatoid arthritis; TNF = tumor necrosis factor.
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Introduction
The management of patients with RA has changed consid-
erably over the past several years. The introduction of new
DMARDs prompted the emerging trend among rheumatol-
ogists to treat RA patients earlier and more aggressively.
The ultimate goal in managing RA is to prevent structural
joint damage and loss of function. Recent evidence sug-
gests that early intervention is important in achieving this
goal. In this new management setting, more attention is
given to the differentiation between RA and other types of
arthritis, particularly osteoarthritis. Initial evaluation of RA
patients should include the risk of developing self-limiting
arthritis, persistent nonerosive arthritis, and persistent
erosive arthritis. In addition, strategies aimed at providing
access to optimal medical care for this patient population
need to be addressed.
To reduce the progression of RA, the vast majority of RA
patients should be treated with DMARD therapy shortly after
the diagnosis. An accurate method of monitoring disease
activity is needed to assess the effect of this therapy. Rapid
and sufficient control of disease activity is needed to prevent
joint damage, loss of function, and to maintain quality of life.
Combination DMARD therapy may, in this respect, provide
additive effects or allow dose reductions to avoid toxicity.
Optimal management also includes patient education and
the involvement of a multidisciplinary team of health care
providers to minimize the impact of the disease on the indi-
vidual’s functional activity. The following is a discussion of
these issues in the treatment of RA patients.
Early RA
Because DMARD treatment is justified only when the risk
benefit is favorable, it is mandatory to differentiate between
Current and future management approaches for rheumatoid
arthritis
Ferdinand C Breedveld
Leiden University Medical Center, Leiden, The Netherlands
Correspondence: Professor Ferdinand C Breedveld, MD, Leids Universitair Medisch Centrum, Stafcentrum Reumatologie, Albinusdreef 2, Leiden
2333 ZA, The Netherlands. Tel: +31 71 526 3598; fax: +31 71 526 6752; e-mail: f.c.breedveld@lumc.nl
Abstract
With the introduction of new disease-modifying antirheumatic drugs (DMARDs) and other therapeutic
agents, the management of rheumatoid arthritis (RA) has shifted toward earlier, more aggressive
therapy. The ultimate goal is to prevent structural joint damage that leads to pain and functional
disability. Early diagnosis of RA is therefore essential, and early DMARD treatment combined with
nonsteroidal anti-inflammatory drugs is recommended. Combination DMARD regimens and new
biologic agents (anti-tumor necrosis factor [TNF] therapies [infliximab, etanercept] and the interleukin
[IL]-1 antagonist [anakinra]) have emerged as viable options for early treatment of RA patients. These
new biologic agents and future nonbiologic agents that target proteins in signaling cascades are likely
to change the landscape of RA treatments.
Keywords: rheumatoid arthritis, disease-modifying antirheumatic drugs, emerging therapies, infliximab
Received: 5 November 2001
Revisions requested: 7 November 2001
Revisions received: 7 December 2001
Accepted: 15 December 2001
Published: 27 March 2002
Arthritis Res 2002, 4 (suppl 2):S16-S21
This article may contain supplementary data which can only be found
online at http://arthritis-research.com/content/4/S2/S16
© 2002 BioMed Central Ltd
(Print ISSN 1465-9905; Online ISSN 1465-9913)S17
Available online http://arthritis-research.com/content/4/S2/S16
RA and other forms of arthritis as early as possible after the
development of symptoms [1]. The 1987 American
College of Rheumatology (ACR) criteria for RA have often
been used as a diagnostic tool in patients with recent-
onset arthritis. However, these criteria were not developed
in patient populations in need of a diagnosis, and therefore
the diagnostic ability in early RA is likely to be suboptimal.
In a collaborative effort, several groups involving data sets
of patients with early arthritis are developing diagnostic
criteria [2]. In these studies, the gold standard for diag-
nostic indicators will be defined by the clinical outcome
after years of follow-up. This activity will provide a set of
criteria that will allow discrimination between self-limiting,
persisting nonerosive, and persistent erosive arthritis early
in the course of the disease. An internationally accepted
diagnostic model will allow construction of a therapeutic
algorithm in which levels of probability for persistent arthri-
tis are linked with choices for DMARD treatment.
Poor prognosis with respect to joint destruction is sug-
gested by early age of RA onset, high titer of rheumatoid
factor, high levels of acute-phase proteins, high numbers
of involved joints, and early occurrence of joint erosions
[3,4]. The presence of these factors indicates a 75%
probability that clinically significant joint damage will
occur. The ability to predict joint damage can be
improved; however, current predictors are already influ-
encing therapeutic choices.
Monitoring of RA
Accurate monitoring of disease progression is mandatory
to assess therapeutic efficacy of agents that slow or
inhibit structural joint damage and limit long-term disability.
Because of the heterogeneity in disease progression
between individual patients, a composite evaluation of a
variety of clinical parameters is needed. The selection of
an evaluation index should be governed by parameters
sensitive to changes that are easy to obtain, are not redun-
dant, and have high predictive attributes for long-term
disease outcome [5].
Both the European League Against Rheumatism and the
ACR have defined core sets of disease activity measures
for RA with the goal of providing uniformity in the assess-
ment of outcome in clinical trials [6,7]. These measures
include tender and swollen joint counts, patient and physi-
cian global assessments of disease activity, acute-phase
reactants, and pain and physical disability assessments.
Each core set has proven viability and reliability, and has a
high level of agreement.
However, these core sets have limitations. The ACR 20%
response criteria (ACR20) are composed of a combina-
tion of ratios and do not provide an absolute measure of
changes in activity. Additionally, the European League
Against Rheumatism Disease Activity Score is complex.
Because of these limitations, these indices have not been
introduced into day-to-day clinical practice for the assess-
ment of RA treatment.
To avoid these limitations, Smolen et al. [8] recently pro-
posed a simplified disease activity score (DAS). Using the
sum score of the tender and swollen joint counts (28 joints),
patient and physician global assessments of disease activ-
ity, and the C-reactive protein level, high correlations are
obtained with validated measures. This simplified index may
be a viable supplement to the core sets and can be imple-
mented in daily clinical practice. In addition, when used in
clinical trials, this index would have an intuitive familiarity,
thereby allowing the practitioner to compare the results of
clinical trials with familiar clinical observations.
Pharmacologic treatment
The initial drug treatment for RA involves the use of salicy-
lates, nonsteroidal anti-inflammatory drugs, or selective
cyclooxygenase-2 inhibitors to reduce pain and improve
motion. Low-dose oral glucocorticoids and local injections
of glucocorticoids are highly effective for relieving symp-
toms in patients with active RA, and prolonged treatment
appears to have disease-modifying properties [9].
However, because these agents do not affect disease
progression, they should not be used as monotherapy in
RA. All RA patients are therefore candidates for DMARD
therapy to prevent structural joint damage and maintain
function. Furthermore, referral from a primary care physi-
cian to a rheumatologist is recommended in the event of
clinical suspicion, as delay induced by the desire for a
confirmation of a diagnosis often results in disease pro-
gression before effective treatment is initiated.
Early initiation of DMARD therapy is advocated to prevent
irreversible structural joint damage. van der Heijde reported
that approximately 75% of RA patients with early disease
have joint erosions or develop erosions within the first
2 years after the onset of symptoms [10]. Three studies
have compared the use of early single-DMARD treatment
with the delayed approach and reported that early introduc-
tion of DMARD therapy is associated with a better
outcome after 1 or 2 years of treatment [11–13]. Further-
more, a recent evaluation of primary data from 14 random-
ized clinical trials in RA patients indicates that patients with
a longer disease history do not respond to DMARD therapy
as well as patients treated at earlier stages of the disease
[14]. Importantly, major side effects of early DMARD treat-
ment are manageable, which supports the conclusion that
all early RA patients should be treated with DMARDs. The
large majority of RA patients are eventually subjected to the
potential side effect of DMARD therapy; it is thus pointless
to delay early treatment that may improve long-term
outcome. Early DMARD treatment may also result in
reduced total health care costs.S18
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The DMARDs most frequently used include methotrexate
(MTX), sulfasalazine, hydroxychloroquine, and leflunomide.
The choice of a DMARD for an individual patient is based
on many factors, including the efficacy/toxicity spectrum of
a drug, monitoring requirements, costs, and patient vari-
ables such as prognosis, comorbidity, and preferences.
MTX has a prominent place in the therapeutic armamen-
tarium of many rheumatologists. A generally accepted
guideline for MTX use is that the drug should be pre-
scribed as monotherapy when initial treatment with
another DMARD has not achieved disease control. On
failure of MTX monotherapy, combination therapy with
MTX and other DMARDs is considered for the next line of
therapy [15].
The most recently approved DMARD is leflunomide
(Arava™; Aventis Pharmaceuticals, Kansas City, MO,
USA), a pyrimidine synthesis inhibitor that has both
immunosuppressive and immunomodulatory effects.
Leflunomide inhibits T-cell proliferation, autophosphoryla-
tion of epidermal growth factor receptors, and activation of
nuclear factor-κB [16,17]. The efficacy of leflunomide was
investigated in three large, phase II clinical trials [18–20].
Leflunomide significantly increased the proportion of
patients who experienced an ACR20 score and signifi-
cantly improved tender joint counts, swollen joint counts,
and physician and patient global assessments compared
with placebo. However, MTX and sulfasalazine were found
to be as effective as leflunomide. Common adverse events
associated with leflunomide included gastrointestinal dis-
orders, alopecia, skin rash, and elevated liver enzymes.
Nevertheless, given the comparable efficacy and the
improved safety profile of leflunomide compared with
MTX, many physicians regard leflunomide as a good alter-
native [20].
Many rheumatologists already prescribe combination
therapy even though evidence to support combination
therapy was limited until recently [21]. Three main strate-
gies are often used in combining DMARDs, and include
parallel, step-up, and step-down regimens. Data from an
increasing number of trials that support combination
therapy have recently been completed. Step-down bridge
therapies that include corticosteroids have been shown to
provide enhanced efficacy with low toxicity [22–24]. In
patients with a long history of disease, leflunomide [25,26]
improved a suboptimal response to MTX, and the triple
combination of MTX, sulfasalazine, and hydroxychloro-
quine appears to be clinically superior compared with the
agents used in monotherapy [27].
Because of the immunosuppressive properties of
DMARDs, the combination of leflunomide with MTX or any
other immunosuppressive agent needs to be closely moni-
tored. Indeed, most of the rare reports of pancytopenia in
patients receiving leflunomide occurred in patients who
had recently discontinued or were receiving concomitant
immunosuppressive agents. Further studies are required
to determine whether any combination of DMARD therapy
provides improved efficacy. Many new therapeutic strate-
gies are being investigated for RA. The most advanced
product under development is the IL-1 receptor antagonist
(anakinra), a biologic agent that has to be administered by
daily subcutaneous injections.
Nonpharmacologic treatment
Reconstructive surgery can provide great improvement for
patients with end-stage joint damage that is causing unac-
ceptable pain or limitation [28]. However, despite the
achievements of pharmacologic and surgical treatment,
many patients are left with residual disability. Regular par-
ticipation in conditioning exercise programs improves
mobility, strength, and well-being, and does not increase
arthritis activity [29]. RA patients may therefore benefit
from a variety of rehabilitation programs.
Recent evaluations suggest that physical therapy, occu-
pational therapy, psychosocial support, and the care of
nurse practitioners and orthopedic surgeons is more
effective when given by a multidisciplinary team [30].
The additional value of team care may be explained by
enhanced communication, the specific mix of profes-
sional expertise, and the increased attention provided to
the patient.
Emerging therapies
Dynamic and fast-growing insights into cell biology and
the understanding of inflammation have resulted in a new
appreciation of the pathophysiology of RA. It is now
believed that RA is mediated by a vast array of cells and
soluble factors that recruit immune cells and perpetuate
inflammation [31]. Although the primary antigen is
unknown, the initial autoimmune response is associated
with an infiltration of T lymphocytes that secrete chemo-
tactic agents, particularly TNF-α and IL-1. These chemo-
tactic agents recruit lymphocytes, macrophages, and B
cells to the synovial interstitium of the joint. Extracellular
signals also activate complex intracellular signaling path-
ways, alter messenger RNA synthesis, and increase the
production of pro-inflammatory cytokines. Increases in pro-
inflammatory cytokines lead to further cell recruitment of
macrophages and the activation of synovial fibroblasts,
chondrocytes, and endothelial cells in a synovial capsule
[32]. Activation of these cell types further increases cell
migration to the area, and leads to more inflammation, car-
tilage degradation, and increased bone resorption.
Developments in molecular biology and computational
chemistry have allowed the design of agents that specifi-
cally target pro-inflammatory cytokines. IL-1 is elevated in
the synovial fluid of RA patients and is thought to con-
tribute to the pathophysiology of the disease [33]. IL-1S19
receptor antagonist is a naturally occurring cytokine that
competes with IL-1 for binding to the IL-1 type 1 receptor,
but does not initiate the IL-1 signaling transduction
cascade on binding to the IL-1 type 1 receptor [34].
Fujikawa et al. [35] demonstrated that IL-1 receptor antag-
onist production is reduced in synovial cells isolated from
RA patients.
Anakinra (Kineret™; Amgen, Thousand Oaks, CA, USA),
a recombinant nonglycosylated form of IL-1 receptor
antagonist, is an approved therapy for RA patients. The
efficacy and safety of anakinra was demonstrated in
three double-blind trials. In those studies, patients
treated with anakinra experienced significant improve-
ments in tender and swollen joint counts, pain scores,
morning stiffness, and radiographic progression
[36–39]. Anakinra treatment was associated with injec-
tion-site reactions, a higher incidence of neutropenia
compared with placebo, and an increased risk of infec-
tion. Interestingly, neutralizing concentrations of IL-1
receptor antagonist reduced the production of IL-6 and
IL-8, but not TNF-α, in rheumatoid synovial membrane
cultures [40]. In contrast, anti-TNF-α antibodies neutral-
ized not only TNF-α levels, but also IL-6, IL-8, and IL-1
levels, suggesting that TNF-α may play a more central
role in the pathophysiology of RA.
This apparent central role of TNF-α has led to the develop-
ment of a new class of agents (anti-TNF antagonists) that
includes infliximab (Remicade®; Centocor, Malvern, PA,
USA), a chimeric monoclonal antibody specific for TNF-α,
and etanercept (Enbrel; Immunex, Seattle, WA, USA), a
fusion protein of the p75 TNF receptor and immunoglobu-
lin G1. Anti-TNF antagonists have been shown to inhibit
the development of polyarthritic disease in collagen-
induced arthritic mice [41,42] and in mice that constitu-
tively express human TNF-α [43].
Etanercept exhibits a lower specificity than infliximab and
binds to both TNF-α and lymphotoxin-α. Nevertheless, the
efficacy of etanercept in the treatment of RA patients was
demonstrated in several phase II/III studies. Moreland et
al. [44] reported that, at 3 months, patients treated with
etanercept achieved significant improvement in swollen
and tender joint counts, morning stiffness, physician and
patient assessment scores, erythrocyte sedimentation
rate, and quality of life.
Further evidence to support the use of etanercept in the
treatment of RA has been reported by Weinblatt et al.
[45]. In that study, 71% of patients treated with
25 mg/week etanercept achieved an ACR20 score at
week 24 compared with 27% of patients treated with
placebo (P < 0.001). Bathon et al. [46] also reported a
significant increase in the number of etanercept-treated
patients achieving an ACR20 compared with MTX.
However, no advantage was seen for etanercept at
6 months. Nevertheless, etanercept slowed joint damage
in patients with early RA by significantly reducing joint
erosion, although no benefit on joint space narrowing was
observed.
Infliximab has also been shown to be effective in the treat-
ment of RA patients. In a phase II trial (ATTRACT study),
428 patients with active RA despite MTX were treated
with or without infliximab. Significant improvements in
swollen and tender joint counts and rheumatoid factor and
C-reactive protein levels occurred at 30 weeks, and were
maintained through week 54 [47,48]. In addition,
response to treatment occurred rapidly, with approxi-
mately 90% of the ultimate responders achieving an
ACR20 after only two treatments (6 weeks). This improve-
ment in clinical score was maintained through week 54
[48]. Importantly, infliximab significantly inhibited joint
erosion, joint space narrowing, and total radiographic
score progression at 54 weeks and through week 102
(P < 0.001) [48,49].
Clearly, anti-TNF therapy provides significant benefit to
patients with RA. However, because TNF is a normal com-
ponent of the immune system, some investigators have
questioned whether blockade of TNF could lead to an ele-
vated risk of infection. Although infections are more
common in the RA population relative to the general
public, there is a concern that anti-TNF therapy may
increase serious infections. Indeed, serious infections and
sepsis have been reported in postmarketing reports in
patients treated with etanercept and infliximab. Further-
more, rare cases of tuberculosis have been reported in
patients treated with TNF antagonists. Nevertheless, with
proper screening and care in observing patients suscepti-
ble to infections, anti-TNF therapy can provide the benefits
of reduced structural joint damage and improved quality of
life for the majority of RA patients.
According to international consensus, patients are candi-
dates for treatment with biologic agents if DMARD treat-
ment fails to achieve disease control [50]. Nevertheless,
studies in selected areas of efficacy, toxicity, and the
general use of TNF antagonists are still needed to help
further define the most appropriate use of these agents.
The success of TNF inhibitors in treating RA suggests that
inhibition of other upstream and downstream members of
extracellular and/or intracellular signaling cascades may
also prove to be of therapeutic benefit.
At present, biologic agents have been shown to be effec-
tive and have the advantage of specificity over other
agents, such as DMARDs. However, the development of
nonbiologic inhibitors with improved safety profiles com-
pared with current DMARDS may lead to improved out-
comes and reduced costs.
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Conclusion
Earlier DMARD treatment and the use of new biologic
agents such as the TNF and IL-1 antagonists have begun
to alter the treatment practices of rheumatologists. Further
experience in the use of these, and of agents not yet
developed, alone and in combination with DMARDs, is
likely to lead to further changes in the manner in which
rheumatologists treat this debilitating disease.
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